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Abstract 
Initially developed in 1992 as an MR imaging agent, the family of protected graft copolymers 
(PGC) is based on a conjugate of polylysine backbone to which methoxypoly(ethylene glycol) 
(MPEG) chains are covalently linked in a random fasion via N--amino groups. While PGC is 
relatively simple in terms of its chemcial composition and structure, it has proved to be a 
versatile platform for in vivo drug delivery. The advantages of poly amino acid backbone 
grafting include multiple available linking sites for drug and adaptor molecules. The grafting of 
PEG chains to PGC does not compromise biodegradability and does not result in measurable 
toxicity or immunogenicity. In fact, the biocompatablility of PGC has resulted in its being one 
of the few 100% synthetic non-proteinaceous macromolecules that has suceeded in passing 
the initial safety phase of clinical trials. PGC is capable of long circulation times after injection 
into the blood stream and as such found use early on as a carrier system for delivery of 
paramagnetic imaging compounds for angiography. Other PGC types were later developed 
for use in nuclear medicine and optical imaging applications in vivo. Recent developments in 
PGC-based drug carrier formulations include the use of zinc as a bridge between the PGC 
carrier and zinc-binding proteins and re-engineering of the PGC carrier as a covalent 
amphiphile that is capabe of binding to hydrophobic residues of small proteins and peptides. 
At present, PGC-based formulations have been developed and tested in various disease 
models for: 1) MR imaging local blood circulation in stroke, cancer and diabetes; 2) MR and 
nuclear imaging of blood volume and vascular permeability in inflammation; 3) optical imaging 
of proteolytic activity in cancer and inflammation; 4) delivery of platinum(II) compounds for 
treating cancer; 5) delivery of small proteins and peptides for treating diabetes, obesity and 
myocardial infarction. This review summarizes the experience accumulated by various 
research groups that chose to use PGC as a drug delivery platform. 
Key words: contrast agent, gaft-copolymer, poly(ethylene glycol), chelate, paramagnetic, 
gadolinium. 
1. Introduction 
PGCs are relatively simple covalent conjugates 
composed of a poly-l-lysine (PLL) backbone which is 
covalently grafted with a plurality of carboxylated 
methoxypoly(ethylene glycol) (MPEG) side chains via 
the N--amino groups of PLL (Fig. 1). The structure of 
graft copolymers that will be reviewed below is 
Ivyspring  
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diferent from di- and multi- head-to-tail block 
copolymers that were previously used for drug 
delivery applications [1-4]. While the latter usually 
form micelles as a result of interaction between the 
hydrophobic blocks, PGC was specifically designed as 
a non-aggregating covalent macromolecular 
garft-copolymer conjugate. As a non-modified 
copolymer, PGC (also known as PEG-gPLL or 
MPEGS-PL) carries multiple positive charges and can 
potentially form polyionic complexes with 
polyanions, e.g. plasmid DNA. A host of other 
copolymers, structurally and chemcially similar to 
PGC, were under consideration as potential non-viral 
gene delivery vehicles in the late 1990s [1-5]. Howev-
er, despite the efficient formation of homogenous 
populations of small (<100 nm) complexes with 
plasmid DNA, the in vitro and in vivo efficacy of in-
tracellular delivery was insufficiently high to grant 
further development of protected graft polycations for 
gene delivery [4].  
 
 
Figure 1. PGC synthesis. Synthesis of a graft copolymer of polylysine and methoxypolyethylene glycol succinate (MPEG)S with 
subsequent modification of free amino groups with diagnostic labels [18] or adaptor molecules for loading of therapeutics (R). The 
synthesis consits of a synthesis of MPEG sulfosuccinimide ester in the presence of water-soluble carbodiimide, acylation of 20-30% of total 
available amin groups of poly-lysine followed by the acylation of amino groups with an activated analog of R (R-x), usually 
N-hydroxysuccinimide ester. 
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The adaptability of PGCs is in large due to the 
existence of multiple sites on the molecule that can be 
readily modified to carry theraputic or diagnostic 
agents (Fig 1, step 2). A second important 
characteristic of PGCs is that they escape the uptake 
during the multiple passes through the 
reticuloendothethial system (RES) i.e., they have long 
circulation times and thus can be described as „long 
circulating agents‟. This characteristic lead to their 
initial use as a carrier system for delivery of 
paramagnetic imaging compounds for magentic 
resonance imaging (MRI) [6]. As such, the use of 
PGCs for in vivo imaging of the blood pool enabled 
visualization of localized morphological and funtional 
abnormalities in vascular permeability that allowed 
detection of local inflammation and blood supply of 
tumors. The initial success of PGC as an MR vascular 
imaging agent lead to its further developemnt of the 
PGC as a drug delivery platform as will be 
summarized in part two of this review. 
2. PGC: synthesis and structure. 
 In general, the synthesis of PGC involves 
covalent grafting of a polyamino acid with multiple 
MPEG ester chains in weakly alkaline buffered 
aqeous solutions. There are several potential synthetic 
pathways that lead to the desired PGC product, i.e. a 
copolymer of a polyamino acid and covalently grafted 
MPEG chains. They are defined by the reactive side 
chain groups of the polyamino acid and specific 
reactivity of functionalized MPEG (Fig. 1). For 
example, several classes of biocompatible 
polycarboxylic acids can be used as the initial 
backbones for further conjugation with terminated 
MPEG chains. Some of these polycarboxylic 
backbones are biocompatible and biodegradable, such 
as poly-L-glutamic [7] or poly-(α,β)-DL-aspartic acids 
derivatives [8]. Others, such as uncharged 
N-(2-hydroxypropyl) methacrylamide copolymers, 
which are frequently used as backbone polymers, are 
non-biodegradable but are biocompatible and 
non-immunogenic [9].  
Polylysine can be synthesized and purified to 
yield homegenous preparations with various 
polydispersity indeces (PDI) and narrow mass 
distribution (i.e. low PD=Mw/Mn). While 
poly-L-lysine (PLL) is readily degradable into smaller 
oligomers by many serine endopeptidases, its poly 
D-enantiomer is not, and thus can be used for 
synthesizing PGCs with limited biodegradability. 
Currently, PLLs with a polydispersity factor of 1.1 are 
commercially available. The synthesis of PLL has been 
perfected through many years of extensive research. 
The synthesis includes a catalytically initiated ionic 
polymerization process of ring opening in 
N-carboxy-(N--benzyloxycarbonyl)-L-lysine anhy-
dride (CBZ-L-lysine NCA) [10]. Most commonly, the 
synthesis is carried out in polar organic solvents in the 
presence of diethylamine as an initiator. Therefore, 
the synthetic product commonly incorporates di-
ethylamide bridges and the resultant PLL polymers 
(especially those with low degree of polymerization) 
are composed of two different monomers. 
Poly(N--benzyloxycarbonyl) lysines can then be re-
acted with other polymers to yield the formation of 
copolymers due to the availability of free reactive 
N--amino groups. One of the popular blocks is acti-
vated PEG diester [11]. A copolymerization of poly 
CBZ-L-lysine results in linear block copolymers that 
are structurally distinct from PGC. These copolymers 
can then be deprotected and the liberated amino 
groups used for covalent modification, if needed. 
Multiple examples of the use of di- tri- and poly- block 
PLL-PEG copolymers for drug delivery systems exist 
in the literature [12-14].  
Carboxybenzyl protective groups on poly 
CBZ-L-lysine can be efficiently removed using HBr 
and the resultant purified hydrobromides can be re-
acted with MPEG derivatives in water since PLL has a 
high water solubility at pH<11. At pH 8.5 PLL, exists 
in extended coil conformation with fewer than 10% 
deprotonated N--amino groups [15]. Extended coil 
conformation of PLL enables efficient access to PLL 
side chain amino groups by hydroxysuccinimide es-
ters of MPEG-succinate. To prevent extensive hy-
drolysis of activated esters of MPEG succinate which 
occur at pH 8.5, we used N-hydroxysulfosuccinimide 
(NHSS) esters of MPEG-succinate which were ob-
tained in water solution after modifying 
MPEG-succinate (MPEGS) with water soluble car-
bodiimide [16]. The obtained esters are more stable 
than N-hydroxusuccinimide esters at pH>7.5. Our 
experience shows that a 25% modification of PLL 
amino groups with MPEGS is sufficient for obtaining 
highly water soluble graft copolymers that can be 
isolated from the reaction mixture by using ultrafil-
tration [17]. The covalent linking of multiple MPEGS 
chains to PLL results in a large increase of the hy-
drodynamic diameter. This enables purification based 
on ultrafiltration through hollow fibers with a 100-300 
kD cut-off, depending on the sizes of the initial PLL 
and MPEGS. Such purification results in a complete 
removal of non-reacted hydrolyzed MPEG esters (i.e. 
MPEG succinate and NHSS). However, the purifica-
tion of the obtained graft copolymer (MPEGS-PL) can 
be delayed until all modifications to the amino groups 
of PLL are completed. This is especially convenient if 
the second (or later) component that needs to be co-
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valently linked to MPEGS-PL is soluble in water or 
water-miscible solvent. For example, an excess cyclic 
anhydride of diethylenetriaminepentaacetic acid 
(DTPA) dissolved in DMSO was used in our original 
protocol for obtaining an MPEG-PL-DTPA conjugate 
that can be used for further modification of the re-
maining amino groups of PL as a means of obtaining a 
long-circulating chelating polymer [18]. Notably, on 
the second stage of the synthesis, undesirable cross 
linking of PL with bifunctional DTPA derivatives may 
be greatly reduced or avoided due to the presence of 
grafted MPEGS chains.  
The second and other reactants that are to be at-
tached to the backbone do not have to be soluble in 
water for successful linking to MPEGS-PL. The above 
conjugate forms stable suspensions in chloroform due 
to MPEG solubility in some non-polar solvents, and 
the amino groups remaining on PL after the modifi-
cation with MPEGS esters can be further covalently 
modified in the presence of an organic base (e.g. tri-
ethylamine). The modified product as a rule is more 
soluble in chloroform. For example, for synthesis of 
PGC carrying hydrophobic fatty acid chains or 
cholesteryl hemisuccinate residues, MPEGS-PL can be 
treated with chloroform-soluble activated esters of 
fatty acids [19]. Insolubility of MPEGS in diethyl ether 
and ethyl acetate can be further used for precipitating 
the obtained PGC conjugates from choroform which 
greatly simplifies the purification from the excess of 
hydrophobic modifier.  
3. Physico-chemical and biological 
properties of MPEGS-PL-DTPA. 
3.1. Molecular mass and size (hydrodynamic 
radius) 
 Highly-soluble polycationic graft copolymer 
MPEGS-PL was initially used by our group to obtain 
MPEGS-PL-GdDTPA (from here on - abbreviated as 
PGC-DTPAGd) designed as a biocomaptible 
non-toxic and long-circulating contrast agent (CA) for 
MRI [6]. The molecule consited of MPEG5 succinate (5 
kD) linked to poly-lysine with a degree of 
polymerization of 250, which was then conjugated to 
DTPA and labeled with Gd3+ using transchelation. 
Protective MPEG chains constitute the bulk of 
PGC-DTPAGd molecular weight (up to 80% by 
weight in the case of PL with 40% amino groups 
modified with 5kD MPEG) [18]. MPEG protective 
chains in diluted water solutions were not expected to 
form coordination bonds with free paramagnetic ions. 
Therefore, the percentage of Gd by weight in 
PGC-DTPAGd is always lower than in PLL-GdDTPA 
prepared from PLL with the same degree of 
polymerization and ranges between 5-6% of dry co-
polymer weight. The calculated longitudinal molar 
proton relaxivity of Gd was similar in the presence or 
in the absence of MPEG chains (i.e. the efficiency of 
Gd to increase longitudinal (spin-lattice) relaxation 
rate of water protons, r1= R1/[Gd]= 12-14 [mmol.s.l]-1 
for poly(l-lysine)-GdDTPA and PGC-DTPAGd at 20 
MHz, 37○C) [18].  
The estimation of mass and effective 
hydrodynamic radius of the obtained graft copolymer 
was necessary for understanding the in vivo behavior. 
Niether linear PEG standards nor protein standards 
were suitable for estimating the mass of 
PGC-DTPAGd. For example, the mass determined 
from elemental analysis is approximately 2-times less 
than the mass determined by size-exclusion 
chromatography (SEC) [20]. The difference between 
the calculated mass of PGC from protein standard 
calibrated-SEC and true mass of PGC is due to the 
significant effect of highly hydrated large MPEGS side 
chains around PL on hydrodynamic diameter of PGC 
(see Fig. 2A). 
3.2. Immunogenicity and toxicity 
 Safety is a major concern in the case of all poly-
mers potentially useful for medical applications, and 
in the case of long-circulating diagnostic agents in 
particular [21]. A number of large macromolecules 
including proteins (serum albumin), synthetic poly-
peptides, polyamidoamines (poly-l-lysine), polyi-
mines and polysaccharides (dextran) can carry diag-
nostic labels and exhibit slow renal filtration (which is 
dependent on the size of the final molecule). Serum 
albumin (e.g. BSA) is a 66 kD protein and has 30-35 N-
 -lysine amino groups that can be potentially 
chemically modified, whereas poly-l-lysine of the 
same mass has more than 500 -lysine residues, with 
the majority of them accessible for chemical 
modification. And although a variety of 
macromolecules can be modified to carry diagnostic 
labels, many of them will have undesirable imaging 
characteristics because of rapid opsonization (i.e. 
binding of complement proteins or 
immunocomplexes), removal by phagocytic cells (e.g. 
monocytes or Kupfer cell of the liver with the aid of 
scavenger or complement receptors), and breakdown 
and early excretion.  
Poly(ethylene glycol) is not toxic for animals 
even at high doses after systemic administration [22]. 
Remarkably, poly(ethylene glycol) and its derivatives 
substantially decrease immunogenicity when 
chemically attached to proteins [23]. It has been 
hypothesised that the modification of surface 
Theranostics 2012, 2(6) 
 
http://www.thno.org 
557 
-aminogroups by highly hydrated polymer leads to 
the masking of potential antigenic determinants of 
proteins (reviewed in [24, 25]. We observed a similar 
effect with polymers containing poly(ethylene glycol) 
grafted to synthetic backbones. Presumably, grafted 
polymeric chains can potentially provide a "hydrated 
shell" for the central polymeric carrier. While 
protein-linked DTPAGd is immunogenic [18, 21], we 
did not observe any significant immune response 
against DTPAGd at either 8 or 15 days after 
PGC-DTPAGd intravenous (I.V.) injection in mice. To 
test the immune response to PGC-DTPAGd 
components, MPEG and DTPAGd were conjugated to 
ovalbumin, which was used for A low-affinity 
response detected on day 8 had diminished by day 15 
(Fig. 2B). Whereas BSA-DTPAGd, used as a positive 
control and injected at a dose similar to Gd, elicited a 
substantial response to DTPAGd.  
Gadolinium-labeled PGC-DTPA did not show 
any detectable toxic effects in two rodent species 
under study. We detected no weight loss or renal 
toxicity in mice injected at 30 times the projected MR 
imaging dose (0.6 mmol Gd/kg, a total of 50 mg 
PGC-DTPAGd/animal, one month observation) or in 
rats injected with a total dose of 0.2 mmol/kg (a total 
of 125 mg of PGC-DTPAGd/animal, 5-6 consecutive 
injections for 2 weeks) [18, 26].  
3.3. Biokinetics and biodistribution of PGC 
labeled with hydrophilic groups. 
 The grafting of long-chain MPEGs results in a 
significant increase in the blood half-life of a backbone 
polyamino acid (e.g. PLL) when compared to 
non-modified PL (Table 1). However, the presence of 
high amounts of MPEG in the aqueus solution of 
PGCs may increase viscosity and hamper i.v. 
administration of concentrated formulations. In an 
attempt to decrease the size of protective chains while 
preserving longievity in blood, we prepared PGC 
with MPEG ranging in mass from 0.75 to 5 kD, and 
tested these compounds in vivo. Our results indicate 
that 2-5 kD MPEGs definitely prolong the circulation 
in vivo while 0.75 kD MPEG does not [20]. A notable 
decrease in renal uptake was observed with the 
increase of MPEG chain length. A biphasic pattern of 
elimination was typical for 2-5 kD MPEG, however, 
0.75kD MPEG-modified PGC exhibited a very rapid 
blood clearance similar to that of PL-DTPAGd with a 
major short phase (blood half-life t1/2= 0.6 h). A 
monoexponential blood clearance was only seen for 
MPEG5-containing PGC. The use of MPEG succinyl 
succinate for grafting allows the introduction of addi-
tional biodegradable ester bonds into the protective 
chains which tend to break down after prolonged 
incubation with plasma, while metal cation chelation 
to DTPA showed excellent stability even in the pres-
ence of an excess of apo-transferrin [17] (Fig. 3A,B). A 
typical time course of PGC-DTPAGd biodistribution 
in rats harboring ectopic mammary R3230 
adenocracinomas is shown in Fig. 3C. The 
biodistribution confirms: 1) long circulation time in 
blood; 2) some residual uptake of PGC in the kidneys; 
3) the uptake of PGC in tumors due to the enhanced 
permeability and retention (EPR) effect.  
 
Table 1. Properties of PGC-DTPA(Gd) synthesized using poly-l-lysine hydrobromide with a degree of polymerization of 
252 and a MW(LALLS) of 41.8 kD. 
MPEGS 
mass  
 
Number MPEGS 
residues/ 
PGC molecule 
Calculated av-
erage mass of 
PGC-DTPAGd 
Apparent mass of 
PGC-DTPAGd, by 
SEC
a
 
Hydrodynamic diame-
ter, mean+SD, nmb 
 Gd, % by weight  Blood 
half-life, hc 
Calculated  Elemental analysis 
0 0 136,000 315,000 NM 24.7  16.6±0.5 0.3d  
750 90 180,000 400,000 NM ND  0.6 15e 
2000 96 300,000 602,000 4.0+2.0 12.0  13.4±0.3 1.1 8.2e 
5000 92 560,000 1160,000 10.3+2.0  6.0  7.0±0.2 14.1d  
a- determined using protein mass standards for SEC;  
b- determined using photon correlative spectroscopy  
c- determined in rats (n=3/ time point), mean values are presented; 
d- monoexponential fitting;  
e- biexponential fitting of experimental data; first value - short component, second value - long  
 component 
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Figure 2. Protective elements in PGC and low immunogenicity. A – an approximate 3D-model of a PGC fragment showing the 
major elements of the graft copolymer structure (courtesy of Terence O’Loughlin, M.D., MGH-CMIR); B – the comparison of immune 
response to DTPAGd conjugated either to a protein (BSA-DTPAGd, open symbols) or to PGC (closed symbols) as determined by ELISA 
of blood plasma (in mice, n=3) using ovalbumin conjugated to DTPAGd for detecting the formation of antibodies. The numbers in 
parenthesis indicate the time interval before Gd injection and ELISA test. Adapted from [18]. 
 
 
 
Figure 3. Resistance to transchelation, degradation in blood, and biodistribution in vivo. A- size exclusion HPLC profiles 
(scintillation radioactivity detector) of 111In-labeled, Gd-saturated sample of PGC-DTPA incubated in saline or PBS/2 mg/ml 
apo-transferrin for 48 h; B- size exclusion HPLC of 111In-labeled, Gd-saturated sample of PGC-DTPA incubated in PBS or whole blood for 
48 h. The arrow shows the shift of the peak migration and the formation of a shoulder indicating biodegradation. C – residual 
blood-corrected biodistribution of PGC-DTPA (111In-labeled, Gd-saturated) in R3230 AC implanted Fisher rats (n=4 for each time point). 
Adapted from [17]. 
 
4. Applications in imaging 
4.1. Quantitative MR and radioisotope imaging 
of blood volume and dynamics  
 Most pathological processes involve changes, at 
some level, in vascular structure or function. In some 
cases (atherosclerosis, stroke, and heart disease), these 
changes cause the disease and in other cases (diabetes, 
cancer, and inflammation) these changes promote and 
exacerbate the spread/pathology of the disease. Thus 
high resolution morphological and functional vascu-
lar imaging is the center stone of radiological methods 
for the diagnosis and staging of multiple diseases, as 
well as in treatment planning and evaluation (such as 
determining the metastatic potential of tumors or the 
amount of salvageable brain area after stroke).  
 Gadolinium labeled PGC (PGC-DTPAGd) ena-
bles high-quality, high resolution images of blood 
vessel morphology [18], in rodents and rabbits [27] 
that can be obtained at various magnetic field 
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strengths (1.5-9.4T), Fig. 4. After injecting 
PGC-DTPAGd, we were able to track arteriovenous 
circulation on the obtained images by using angio-
graphic MR pulse sequences. Both the arteries and 
veins of small diameter (0.25-1 mm) became readily 
discernible for 3 h after the injection. We achieved a 
level of contrast equivalent to that achieved by the 
low mass contrast agent DTPAGd, but at a much 
lower dose of Gd (20 µmol PGC-DTPAGd versus 
100-200 µmol DTPAGd). With the introduction of 
high field MRI (9.4T) much higher signal-to-noise 
images could be obtained by injecting approximately 
0.15 mmol PGC-DTPAGd/kg (Fig 4). We further 
demonstrated the feasibility of PGC-DTPAGd assist-
ed detection of slow gastrointestinal bleeding [28]. In 
the above model study we showed that at a dose of 35 
μmol/kg PGC-DTPAGd we could clearly delineate 
small volumes of blood in the gastrointestinal (GI) 
tract (stomach and small intestine), whereas the same 
volume of Gd-free blood was not detectable. These 
results demonstrate that due to the long blood half life 
of PGC, blood pool imaging can potentially be helpful 
in detecting venous as well as arterial bleeding and in 
imaging intermittent GI bleeding over time.  
 The advantages of DTPAGd-labeled PGC for 
determining blood flow and blood volume in animal 
models of disease have been assessed in several 
studies [29, 30]. Unlike radiochemical CAs, the signal 
changes generated by MR blood pool agents do not 
directly reflect their concentration since MR signal 
changes do not arise due to CA itself but instead are 
the consequence of CA effects on relaxation properties 
of surrounding proton spins. Because water exchange 
occurs between blood and the extravascular space, 
protons of water molecules carry magnetization out of 
the blood and into the extravascular space, rendering 
inaccuracies in the calculation of hemodynamic pa-
rameters. In an effort to offset these inaccuracies, most 
studies of blood flow and volume make a priori as-
sumptions about the proton exchange rate (that it is 
either zero or rapid) for the organ or system under 
investigation. The use of a strictly intravascular CA 
such as PGC-DTPAGd allowed estimating the accu-
racy and precision of blood volume measurements 
[31]. When assuming fast exchange of protons be-
tween blood compartments, the true blood volume 
was generally overestimated and when assuming 
slow or no exchange the opposite was true (an un-
derestimation occurred). As for the use of 
PGC-GdDTPA in measuring blood volume, we found 
that the best approach was to assume contributions 
from fast and slow proton exchange to be equal while 
carefully selecting imaging parameters. Such consid-
erations were found to be of upmost importance in the 
accurate assessment of blood volume in an animal 
model of tumor neovascularization (see section 4.2). 
 
 
Figure 4. Imaging of vascular supply using PGC-DTPAGd. A- maximum intensity pixel (MIP) projection image of blood 
circulation in a mouse obtained using gradient-echo pulse sequence (1.5T, GRASS, TR/TE 60/8, FA 60, 2NEX, 8 cm field of view) after 
injecting PGC-DTPAGd at 25 µmol Gd/kg; B- a MIP image showing circulation in the head of a rat (imaging parameters similar to that of 
A); C – an improvement in imaging detail of rat cerebral circulation at 9.4T results from increased dose of PGC-DTPAGd (150 µmol 
Gd/kg) due to the lower molar relaxivity of Gd3+ at high magnetic fields. Adapted from [18, 103]. 
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 Based on the above findings we assessed trans-
vascular water exchange in an acute stroke model 
using PGC-DTPAGd [32]. Because low molecular 
weight DTPAGd permeates the compromised brain 
vessels, its presence in the extravascular space is 
widely used for detecting this pathology in stroke. 
However early brain ischemia may not be detectible 
using conventional DTPAGd-enhanced MR angi-
ography [33] [34]. We measured the early movement 
of water molecules out of the vasculature in mice with 
middle cerebral artery occlusion by acquiring MR 
images after the injection of PGC-DTPAGd. We found 
that water exchange across the vessel walls increased 
early (within 1h) after the middle cerebral artery oc-
clusion and apparent diffusion coefficient (ADC) 
values in the same brain regions decreased over time 
consistent with the progression of edema due to in-
creased intracellular volume.  
 Subsequently we tested a similar PGC com-
pound obtained by chelating the paramagnetic metal 
dysprosium with PGC-DTPA. We found that a blood 
volume-dependent tissue signal (generated by T2- or 
T2*-weighted pulse sequences) can be monitored 
continuously, without interfering with arterial spin 
labeling technique, thereby allowing simultaneous 
blood volume and cerebral blood flow measurements 
(CAPTIVE imaging) [35]. Due to a very low r1 of 
dysprosium PGC-DTPADy does not interfere with the 
ASL induced signal, and thus affords an advantage 
over imaging with DTPAGd. CAPTIVE allowed high 
spatial resolution imaging of blood flow and volume 
changes occurring after middle cerebral artery occlu-
sion in rats and these hemodynamic changes could be 
correlated with ischemia induced tissue damage. In a 
separate study [36] the CAPTIVE method was used 
successfully to measure hemodynamic changes dur-
ing hemorrhagic hypotension.  
Collectively, our results with PGC as a carrier for 
MR imaging CAs suggest that steady-state imaging 
with long-circulating agents potentially has important 
advantages for a number of MR clinical applications. 
These should be of greatest utility in cases such as 
stroke and GI bleeding when timely diagnosis is key 
to positive patient outcome.  
 We have also developed PGC-DTPA for blood 
pool imaging in nuclear medicine applications. We 
hypothesized that the availability of a long-circulating 
synthetic molecule that could be easily labeled with 
gamma-emitting isotopes would obviate the need to 
use human blood components as carriers for isotopes 
and therefore would be a substantial improvement in 
patients' and operators' safety. Our major expectation 
was that PGC-DTPA could be formulated into a kit 
form which needs only the addition of pertechne-
tate-99m solution to obtain a [99mTc]-labeled injec-
tion-ready preparation for imaging left ventricular 
ejection fraction in oncology patients undergoing po-
tentially cardiotoxic treatments [37].  
 To obtain a labeling kit, we combined 
PGC-DTPA with a buffering solution in the presence 
of Sn(II) to enable reductive conversion of pertechne-
tate to a Tc oxocomplex [37]. After testing the kit in 
vitro and in three animal species [37] (representative 
SPECT/CT image in rats Fig. 5A) we tested 
PGC-DTPA[99mTc] in a phase I clinical trail that 
showed promising results. Twenty mCi (70 MBq) of 
the compound were injected I.V. and serial anterior 
and posterior whole body images were collected im-
mediately and after a delay [38] (Fig. 5B). The com-
pound showed the expected distribution and the 
heart and major blood vessels were clearly distin-
guishable up to 24 h post injection. The blood half life 
of the compound was 20.6 ± 2.3 hr. In four of the 
volunteers 22.1% ± 2.5% of the compound had been 
excreted through the kidneys 24 hr after iv admin-
istration, while the other two volunteers showed a 
greater distribution of the agent to the liver and 
spleen presumably due to DTPA labeling instability 
and not due to immunogenicity. A combination of the 
PGC long blood half-life with the advantages of a 
simple labeling protocol make this synthetic copoly-
mer kit a potential substitute for blood products in 
blood pool imaging under the conditions when other 
blood pool imaging modalities fail to produce ade-
quate results.  
4.2. Imaging of tumor neovascularity. 
 Neovascularization is one of the key character-
istics of tumor growth [39]. Although neovascularity 
of a solid tumor does not necessarily imply 
malignancy, extensive sprouting of capillaries in 
malignant tumors has been shown to correlate with 
metastatic potential [39]. Non-invasive detection of 
altered tumor vessels is potentially important in bi-
opsy planning, staging and in treatment evaluation 
(since decreased vascularized margins can be indica-
tive of tumor regression). We initially used 
PGC-DTPAGd-assisted MR imaging for detecting the 
increase of the diameter of host vessels, e.g. epigastric 
vein, as an early sign of tumor progression in a rat 
model of mammary adenocarcinoma [40]. Six to 8 
days after tumor implantation, vessels at the tu-
mor/host interface became clearly visible by MRI. At 
later stages of tumor development, we observed for-
mation of tumor blood vessels with abnormal mor-
phology (Fig. 6A-C). Time-delayed imaging of the 
same animals (48 h post IV administration) revealed 
the enhanced leakage of PGC from immature and 
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permeable tumor blood vessels (Fig. 6D-F) Therefore, 
PGC-DTPAGd-generated vessel enhancement of MR 
signal is effective in tracking the developing vascular 
tumor architecture non-invasively in vivo. The 
method is sensitive in the whole volume of the tumor 
at even early time points and has the capacity to be 
instrumental in detecting areas of enhanced vascular 
permeability.  
 We further tested whether PGC-DTPAGd dis-
tribution reflects tumor and interstitial relative blood 
volume fractions in a model of rat glioma [41]. We 
used consecutive I.V. injections of PGC-DTPAGd and 
DTPAGd where the first injection selectively saturates 
the blood signal so that the second I.V. injection of 
DTPAGd alters the MR signal of the tumor interstit-
ium due only to its escape through abnormally per-
meable vessels of the tumor. Therefore, a simple sub-
traction of MR images obtained using the two contrast 
agents allowed mapping of relative vascular (VVF) 
and relative interstitial volume fraction (IVF) of the 
tumor within the same imaging slice, assuming very 
slow water exchange between compartments (which 
is valid given the use of specific pulse sequences). We 
were able to map patterns of intratumoral and inter-
tumoral heterogeneity of both volume fractions at 
submillimeter pixel resolution and these patterns 
agreed with tissue histology data. 
 
 
 
Figure 5. PGC as a blood pool imaging agent. A- a fusion SPECT/CT image of a rat 30 min after the injection of 99mTc-labeled PGC 
(2 mg PGC-DTPA/kg, 1 mCi 99mTc/rat). The image was obtained using NanoSPECT/CT (Bioscan Inc.); B- an image obtained in a healthy 
volunteer during Phase I clinical trials. Serial anterior whole-body images are shown taken immediately (30 min) and 2 h after the injection 
of 25 µg PGC-[99mTc]DTPA/kg (total dose - 20 mCi 99mTc). Note the distribution in the blood pool and low uptake in the lung, spleen and 
liver. Adapted from [38]. 
 
Theranostics 2012, 2(6) 
 
http://www.thno.org 
562 
 
Figure 6. MR imaging of tumor neovascularity and interstitial leakage in a rat model of adenocarcinoma. A-C- a MIP 
projection (A) and two non-consecutive MR imaging slices obtained 30 min after I.V injection of PGC-DTPA(Gd) in rats with R3230 
adenocarcinoma. D-F – MR images obtained in the same animal 48 h after the injection of PGC-DTPAGd. Note accumulation in the tumor 
at 48 h (the location of the tumor is shown by arrowheads). For MR imaging conditions see Figure 4A, legend. Adapted from [40]. 
 
 
 The use of PGC-DTPAGd was further refined 
for measurement of absolute blood and interstitial 
volumes in a murine model of prostate cancer [42]. 
The measurements of blood and interstitial volumes 
calculated from Gd-based methods could be skewed 
when a prior assumptions of either large or negligible 
water exchange between the inter and extravascular 
compartment were made [31]. The is primarily due to 
the fact that some tumors (for example rat brain 9L 
gliosarcoma model) have significantly different water 
exchange rates than the surrounding normal tissue. In 
this study, we modeled a range of water exchange 
rates in order to establish a more precise method for 
quantification of absolute blood and interstitial vol-
ume in mice bearing slow growing MDA PCa 2b 
prostate tumors. Results showed that unlike more 
aggressive tumors, MDA PCa 2b tumors have very 
similar intra-/extravascular water exchange rates and 
blood volumes for tumor and non-tumor compart-
ments. This raises the intriguing possibility that a dual 
tracer method using a large molecular weight, strictly 
intravascular CA such as PGC-DTPAGd in combina-
tion with DTPAGd may allow differentiation of ag-
gressive versus slow-growing tumors. In a model of 
MCF-7 mammary adenocarcinoma overexpressing 
VEGF, PGC-GdDTPA revealed significantly higher 
vascular volume fractions in VEGF expressing tumors 
(8.9 ± 2.1) compared to control tumors (1.7 ± 0.5, 
p<0.003). VEGF overexpressing tumors had 1.6 fold 
higher microvascular density as assessed by histology 
[43]. Overall, the ability to separately measure relative 
vascular and extravascular tissue volume fractions in 
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the same study may provide new algorithms for as-
sessing tumor aggressiveness and response to treat-
ment. In addition, because the size and make up of the 
tumor insterstitial volume will affect the ultimate 
concentration and distribution of chemotherapeutics 
that extravasate from the blood pool and reach the 
tumor, the knowledge of the IVF will be important in 
treatment planning and assessment of tumoral re-
sponse to therapy.  
 In view of the latter, PGC-DTPAGd is especially 
useful for monitoring anti-angiogenesis. Since our 
studies in a tumor model overexpressing VEGF 
demonstrated a pro-angiogenic increase of tumor 
blood volume, we tested whether PGC-DTPAGd can 
also be used to detect anti-angiogenic effects of the 
experimental VEGF type 2 receptor tyrosine kinase 
inhibitor (VEGFR2-TKI) [44]. By using a steady-state 
blood pool imaging technique we were able to detect 
a very early decrease in tumor blood volume (Vb) 
after treating mice with two doses of VEGFR2-TKI, 
which in turn resulted in a decrease of vascular den-
sity and tumor cell apoptosis (Fig. 7A,B). By measur-
ing the dependence of Vb measurement on flip angle 
using a gradient echo pulse sequence, we determined 
that in ectopic and orthotopic colon adenocarcinomas, 
a Vb change from 2.4% to 1.1% (at high flip angle of 
80o [45]) was detectable only in tumors as opposed to 
the normal muscle blood volumes, which were not 
decreased by VEGFR2-TKI treatment (Fig. 7C). 
Alongside with Vb, water exchange across the blood 
vessel wall, reflected by the slope of Vb dependence 
on flip angle, was also decreased in treated tumors 
but not in the muscle (Fig. 7C).  
Stable synthetic peptides derived from type 1 
repeats of thrombospondin (TSP1) are a second class 
of molecules that we have tested for antiproliferative 
effects in a rat model of glioma [46]. After treating 
animals with TSP-1 derived peptides, we observed 
suppression of glioma growth that coincided with 
apparent inhibition of de-novo blood vessel for-
mation, i.e. according to our PGC-DTPAGd enhanced 
MR imaging, TSP-1 derived peptides did not induce 
anti-angiogenesis but instead resulted in angiostasis. 
More recent MR studies have used both fluorescence 
and PGC-DTPAGd assisted MRI to show a reduction 
in functional de-novo vessel formation occurring after 
adoptive transfer of GFP/Noggin-expressing human 
endothelial cells in immunocompromised mice [47]. 
The effect of Noggin (a potent antagonist of bone 
morphogenetic protein signaling) on tumor prolifera-
tion and metastases awaits further study, but should 
be readily assessed with the use of PGC-DTPAGd 
-based perfusion imaging methods. 
 
Figure 7. PGC-DTPAGd in imaging of anti-angiogenesis. A,B- histology of MV522 tumors prior to (A) and after treating animals 
with VEGFR2 tyrosine kinase inhibitor (TKI). Anti-CD31 staining (blue) reflects changes in vascular diameter and density. C – The 
dependence of absolute tissue blood volume fraction (Vb), measured after the injection of 50 µmol Gd/kg of PGC-DTPAGd from flip angle 
of MR SPGR pulse sequence that reflects changes of Vb due to TKI treatment. The slopes reflect changes in water exchange rates across 
the blood vessel wall. Adapted from [44]. 
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4.3. Imaging the tumor microenvironment  
 Some of the properties of the tumor environ-
ment can potentially be imaged by using probes that 
respond to altered expression of hydrolases due to 
tumor-mediated recruitment of stromal cells in re-
sponse to rapid extracellular matrix remodeling, lo-
cally elevated angiogenesis, and apoptosis. Specifi-
cally, protease expression and resultant extracellular 
matrix remodeling are regulated by complex interac-
tions between extracellular matrix components and 
cells populating the tumor, including mesenchymal 
and hematopoetic stromal cells [48].  
This has been initially demonstrated by conju-
gating a near-infrared fluorescent (NIRF) dye, Cy5.5 
to PGC instead of GdDTPA (Fig. 8A).  
 
Figure 8. PGC-based protease-sensing optical imaging probe. A – a computer-generated model (Molecular operating 
environment, MOE) of a Cy5.5 cynaine dye-conjugated PGC showing 12 MPEG protective chains linked to a PL backbone (degree of 
polymerization - n=50) with the rest of N--amino groups modified by cyanine dye. A molecule of trypsin (a model serine protease, m.w. 
22 kD) is shown for comparison. The modeling was performed assuming a tetramolecular water hydration layer which is not shown 
(Laboratory of Molecular Imaging Probes, University of Massachusetts Medical School); B – change of Cy5.5 absorbance spectra before 
and after the trypsinolysis of N--cyanine modified PGC; C – the increase of Cy5.5 fluorescence excitation and emission values after 
treating PGC-Cy5.5 with trypsin which translates into an increase of fluorescence intensity detectable with imaging after the trypsinolysis 
(inset, , -T – in the absence and +T in the presence of trypsin). Adapted from [49]. 
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NIRF dyes are advantageous for in vivo optical 
imaging due to higher transmittance of the tissues in 
the near-infrared range of the spectrum (700–850 nm) 
as opposed to visible light, and lower emission of in-
herent biomolecules, thus allowing imaging of deeper 
tissue. In its native state, the PGC-Cy5.5 protease 
sensing probe has Cy5.5 molecules attached to the PL 
in close physical proximity and in a quenched state 
thereby preventing the dyes from emitting fluores-
cence upon light activation. After injection into tumor 
bearing animals, the probe accumulates in tumors due 
to high vascular permeability, and is subsequently 
exposed to high levels of tumor associated proteases. 
The poly-L-lysine backbone of the probe is readily 
cleaved by serine proteases, which apparently can 
gain access to the backbone poly-l-lysine due to rela-
tively small diameters of the protein molecule (Fig. 
8A), thereby freeing the Cy5.5 and rendering PGC 
fluorescent, due to degradation of the copolymer and 
physical separation of the quenched fluorophores 
(Fig. 8B,C).  
In initial tests, this protease-sensing approach 
resulted in tumor associated fluorescence which was 
12 times higher than surrounding tissue and that al-
lowed detection of tumor xenographts in vivo [49, 50]. 
A family of cysteine proteases (possibly cathepsins B, 
H, or L) were determined to be the activating enzyme 
in this study although other proteases have since been 
shown to be detectable using specifically designed 
PGC based probes in a number of experimental mod-
els of cancer including those expressing cathepsin D 
[51, 52], matrix metalloproteinase [53-55], urokinase 
plasminogen-activator [56, 57] and caspase-1 [58]. The 
strength of this approach is that PGC attachment af-
fords the accumulation of the probe in the tumor, 
while the cleaved products are sequestered in cells 
and tissues, thus allowing the amplification of signal 
over an extended time span (>24 hrs). Subsequent 
studies showed that the probe was taken up in some 
tumor cells but was mainly present in stromal cells 
recruited to the site of tumor formation (fibroblasts, 
monocytes/ macrophages, and dendritic cells) [59].  
 High molecular weight activatable probes 
should have a number of advantages in detection of 
tumors accessible to clinical optical imaging applica-
tions (i.e., those within 7-10 mm of the skin surface 
such as breast, prostate, and colon cancers), especially 
given the demonstrated sensitivity of these probes 
(detecting subnanomole levels of tumor-associated 
enzymes). These probes may prove valuable in dif-
ferential diagnosis and staging of cancers. For exam-
ple, cathespsin B-PGC probes allowed visualization of 
differential cathespin B expression in a 
well-differentiated human breast cancer (BT20) and a 
highly invasive metastatic human breast cancer 
(DU4475) in mice. Both types of breast cancers acti-
vated the NIRF probe so that tumors became readily 
detectable. However, in tumors of equal size, there 
was a 1.5-fold higher fluorescence signal in the highly 
invasive breast cancer which correlated with a higher 
cathepsin-B protein content [60] (Fig. 9). Furthermore, 
these probes should have utility in assessing thera-
peutic response as indicated in a study that proved 
feasibility of PGC-based metalloproteinase-3 sensing 
probe for detecting the effect of oncolytic adenovirus 
in tumors [55].  
 
 
Figure. 9. Imaging of PGC-Cy5.5 breakedown in mammary adenocarcinoma tumors. A- the immunoblot demonstrating a 
higher level of cathepsin B expression in DU4475 than in BT20 tumors, with the band integration profiles shown below the image of a blot. 
Reproduced with a permission from [60]; B – ex vivo planar imaging of Cy5.5 fluorescence in adenocarcinoma samples and the 
corresponding in vivo image of orthotopic tumors implanted in the same animal bilaterally (shown by yellow arrowheads). The animals 
were injected with 2 nmol of Cy5.5 conjugated to PGC 24 h prior to optical imaging. 
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4.4. Imaging markers of inflammation, 
atherosclerosis and diabetes 
 Diseases with different etiologies often share 
common pathological phenotypes due to activation of 
the body‟s innate defense system which is triggered 
by nearly all external and internal insults. For exam-
ple, vascular changes such as increased vascular 
permeability accompany many diseases as the body 
attempts to increase blood flow to sites that will re-
quire efficient crossing of endothelial barriers by the 
cells of the immune system. Thus the PGC-based im-
aging agents described thus far may have utility in 
detecting a wide range of diseases because of their 
extravasation that is highly atypical in normal tissues. 
When used to detect E. coli induced infections in rats, 
Gupta et al [61] found that PGC-DTPAGd yielded 
higher relative signal than [111In] labeled IgG due to 
the lower accumulation of PGC in normal muscle 
tissue, and PGC-DTPAGd yielded similar signal rati-
os when compared to [111In]-labeled white blood cells 
and [99mTc]-labeled chemotactic peptides. Increased 
vascular permeability in infected tissue was regarded 
as the main reason for increased probe concentration 
in these areas. Similar permeability changes were de-
tectable with high-field MRI in the pancreatic vascu-
lature of type 1 diabetic rats [62], suggesting that MR 
imaging may be useful in detecting very early chang-
es in pancreatic vasculature that are believed to pre-
cede the onset of full disease.  
 PGC-based NIRF probes designed to target in-
flammation specific molecules have also been evalu-
ated in animal models of osteo- and rheumatoid ar-
thritis. The disease is characterized by early inflam-
matory responses in which the release of ma-
trix-degrading enzymes (e.g., matrix metalloprotein-
ases (MMPs), cysteine proteases and cathepsin B), into 
the synovial fluid cause the destruction of arthritic 
joints due to the degeneration of proteoglycan and 
type II collagen. These events occur before morpho-
logical changes in joint structure can be detected. In 
two separate studies, cathepsin B activated NIR probe 
(PGC-Cy5.5) injected 24 hr prior to imaging resulted 
in a 3-fold increased fluorescence signal intensity in 
the affected joints of animals with experimentally in-
duced arthritis as compared to control animals [63, 
64]. In arthritic animals treated with the an-
ti-inflammatory drug methotrexate (35 mg of 
MTX/kg 48 hours prior to probe injection), a signifi-
cantly lower fluorescent signal was observed as 
compared with untreated arthritic animals [63]. Alt-
hough X-ray and MRI have established utility in as-
sessing the progression of arthritis, these imaging 
methods detect changes only in more advanced dis-
ease. Thus NIR imaging of protease activated probes 
may offer an advantage in detecting the earliest 
changes in the disease, when anti-inflammatory 
therapy has the greatest chance of limiting joint 
damage. In a more recent study, an altered form of the 
probe was used in which poly-D-lysine replaced 
poly-L-lysine and a cathepsin K sensitive peptide 
linker (GHPG-GPQGKC) was used for attachment of 
Cy5.5. This configuration resulted in a probe that was 
activatable only by cathepsin K [65], and was subse-
quently shown to detect osteoclast-derived cathepsin 
K mediated bone degradation, which is largely re-
sponsible for bone resorption. 
 Atherosclerosis is another highly prevalent dis-
ease that is now considered to be largely linked to 
vascular wall inflammation, and that may be detecta-
ble in its early stages with long circulating protease 
sensitive PGC based probes. An early pathological 
sign of the disease, the fatty streak, is an inflammatory 
lesion which is caused by the accumulation of mono-
cyte-derived macrophages and T lymphocytes [66]. 
The final (and often fatal) sequelea of the disease, 
plaque rupture, is also associated with inflammation 
and has been correlated with the presence of highly 
activated macrophages [67, 68] which release proteo-
lytic enzymes that hasten plaque erosion and rupture. 
Experimentally induced atherosclerotic lesions in 
mice were successfully imaged using fluores-
cence-mediated tomography (FMT) after the injection 
of PGC-based “activatable” near-infrared fluores-
cence (NIRF) probes for cathepsin B [69] and matrix 
metalloproteinases (MMP2 and MMP9) [70]. Histo-
logical analysis showed co-localization of the probes 
with the targeted enzymes and with activated mac-
rophages. In addition, the probe mediated signal in-
crease could be diminished after treatment with pro-
tease inhibitors [70]. MMP sensitive probes have also 
been used to detect inflammatory responses occurring 
after myocardial infarction in mice [71].  
5. Applications in drug delivery 
5.1. Synthesis and applications of 
PGC-covalently linked drugs 
 Developments in synthetic chemistry and nan-
otechnology as well as improvements in the ability to 
re-engineer intrinsic biomolecules, have supplied the 
field with a number of promising drug delivery sys-
tems. Ideally, these systems should be capable of 
protecting the active therapeutic as it travels to its 
organ of destination and then releasing the payload in 
full so that the drug concentration at the site of action 
is equivalent to the administered dose. When admin-
istered directly into the circulation, the drug-carrier 
complex should ideally exhibit low binding to serum 
proteins and be resistant to immediate uptake by the 
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reticuloendothelial system of the liver and spleen, or 
to rapid elimination by the kidneys. Passage of the 
drug through the tight junctions of the vascular en-
dothelial barrier and into the interstitium is another 
necessary step for delivery of a therapeutic molecule 
to its cellular destination. Ultimately, these character-
istics are conferred by the biochemical properties of 
the drug (such as its molecular weight and charge), 
and can also be influenced by the disease process it-
self. For example, many high molecular weight drug 
conjugates are known to accumulate in tumors to a 
greater extent than their free drug counterparts. This 
phenomenon termed “enhanced permeability and 
retention (EPR)” [72, 73] occurs because abnormal (i.e. 
„leaky‟) vascular structure in tumors are highly per-
meable to high molecular weight drug conjugates.  
 Methods for encapsulating therapeutic com-
pounds (such as the use of liposomes or polymeric 
micelles) and for targeting these compounds to spe-
cific tissues and cells (such as attachment of antibod-
ies) have greatly widened the rage of compounds that 
can now be considered for development as therapeu-
tics [74].  
 The development of protected graft copolymers 
has made available a new and potentially very flexible 
method for drug delivery. The potential for use of 
PGC based compounds as drug delivery agents is 
related not only to their ability to carry therapeutic 
molecules in a non-specific manner (“passive target-
ing”) through the vascular system and into the inter-
stitium, but to their ability to be modified so as to se-
lectively target molecules in the extracellular space 
(such as adhesion molecules or enzymes) or on the 
cell surface (i.e. “active targeting”). We have found 
that PGCs have a slow rate of biodegradation, are 
biocompatible (show low immunogenicity) and are 
eventually eliminated from the body after cleavage 
into small fragments. Additional advantages of PGCs 
include: 1) they accumulate at sites of high vascular 
permeability, 2) they are large enough to escape glo-
merular clearance (> 4nm in diameter) even when 
bound to drug, 3) they have a very slow RES clearance 
rate, and 4) they can potentially decrease immuno-
genicity of the drug to which they are bound.  
  Somewhat surprisingly, the capacity of 
PGC to „passively‟ accumulate in tumors was found to 
be as high as that of an antibody targeted drug 
conjugate [75]. Using radionuclide and fluorescent 
labeled derivatives of PGC and BR96 (a tumor-specific 
chimeric monoclonal antibody [76]) we found that 
PGC slowly accumulated in LX-1 human small cell 
lung carcinoma xenografts (Fig 10A) within a 48 h 
period (to 5.2 ±1.7% of the injected dose per gram of 
tissue), while the antibody accumulation peaked at 24 
h and was only slightly higher at 6.0± 3.2% ID/g 
(Fig.10B). Tumoral tissue distribution studies showed 
that roughly 43.9% of the PGC was associated with 
the tumor cell fraction while the remainder had ac-
cumulated in the interstitium. The large accumulation 
of PGC in tumor cells is likely due to its extravasation 
from leaky tumor vascular and subsequent retention 
in the tissue which serves as a depot for prolonged 
fluid phase endocytotic uptake by the cells. This hy-
pothesis is supported by in vitro studies showing that 
the copolymer showed negligible binding to the cell 
surface as compared to the antibody which showed 
high affinity binding (Kd of 4.5 x 10-7 M) followed by 
active vesicular internalization. In a subsequent study 
by Choi and colleagues [77], this approach for 
achieving high concentrations of PGC bound drugs in 
tumors was shown to have therapeutic applicability 
when used to accumulate chlorine e6 (Ce6) in tumors. 
Ce6 is a porphyrin-based molecule that can be excited 
by light to emit fluorescence and simultaneously 
produce cytotoxic singlet oxygen, which causes local 
tissue damage. When used to treat xenografted 
HT1080 fibrosarcoma tumors in mice, a single dose of 
PGC-Ce6 followed by phototherapy was sufficient to 
decrease the tumor proliferation rate by one half.  
 In order to render PGC molecules more appli-
cable for the diagnosis and treatment of diseases that 
are not characterized by leaky vasculature, PGC can 
be targeted to specific tissues and cells by conjugation 
to antibodies and other targeting moieties. PGC 
probes were successfully targeted to cultured human 
endothelial cells by conjugating the F(ab‟)2 fragment 
of monoclonal anti-human E- selectin monoclonal 
antibody (H18/7 [78]) to PGC modified by the addi-
tion of either a sulfhydryl-reactive terminal vinyl-
sulfonate group or a terminal carboxyl group [79] 
(Fig. 11A). The two conjugation strategies resulted in 
compounds with similar antibody/PGC ratios and 
apparent hydrodynamic radii. When added to human 
cultures, 125I labeled F(ab‟)2-PCG showed a binding 
affinity to HUVEC cells expressing high levels of 
E-selectin (after interleukin 1β mediated activation) 
that was 25 to 30 fold larger than the non-specific up-
take observed for non-stimulated HUVEC cells (Fig. 
11B,C). Furthermore the binding yield of the conju-
gate (expressed as a per cent of the total added anti-
body fragment) was almost 25% higher than for free 
F(ab‟)2 indicating that conjugates with the higher 
F(ab‟)2 content were preferentially bound to the cell 
surface due to the increased avidity effect. This tar-
geted PGC probe should have indications for in vivo 
imaging of a host of diseases in which E-selectin ex-
pression is upregulated in association with inflam-
mation and angiogenesis.  
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Figure 10. Targeted antibody and non-targeted PGC accumulation in the same LX-1 non-small cell lung carcinoma 
model. A – a time course of 111In-labeled monoclonal internalizing antibody BR96 and PGC uptake in LX-1 cells; B – biodistribution of 
111In-PGC (blue bars) and 111In-BR96 (grey bars) in LX-1 xenografts after intravenous injection in LX-1 bearing mice at 24h (n=4 
animals/time point). Adapted from [75]. 
 
Figure 11. Human 
endothelial cell 
activation-dependent 
uptake of anti-E-selectin 
conjugated PGC. A – 
synthesis of anti-E selectin 
targeted PGC using 
SATA-modified F(ab’)2 
antibody fragment 
conjugated to 
heterobifunctional 
PEG-linkers carrying vinyl 
sulfone groups; B – 
comparative uptake of 
non-conjugated F(ab’)2 
antibody fragments and 
PGC- F(ab’)2 conjugate; C – 
fluorescence microscopy of 
IL-1 activated and 
non-activated cells 
demonstrating the uptake of 
both Cy5.5-labeled antibody 
fragment and PGC- F(ab’)2 in 
LX-1 cells. Adapted from 
[79]. 
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5.2. PGC- cisplatin complex and anti- 
proliferative activity  
 Our initial attempt at modifying PGCs for use in 
drug delivery entailed the synthesis of an adduct of 
the antineoplastic drug cis-diamminedichloro-
platinum(II) (cDDP) and PGC [80]. cDDP and other 
antineoplastic drugs containing platinum are effective 
cancer treatments due to their ability to cross-link 
DNA and thus inhibit division/ proliferation of 
malignant cells [81]. The motivation in creating a 
modified form of cDDP was to increase the 
bioavalibility of the drug after I.V. administration 
which is otherwise very low due to cDDP‟s rapid 
clearance by the kidney and irrevesible high affinity 
binding to plasma protiens [82, 83]. We also 
hypothesized that binding to PGC would decrease the 
non-specific toxicity of the drug. Since Pt(II) is known 
to form complexes with carboxyl residues of poly-
carboxylic acids, we hypothesized that succinyl resi-
dues attached to the backbone PGC with succinylated 
amino groups will similarly bind the aquated plati-
num(II)-diammine complex. We found that simple 
co-incubation of cDDP (12 mg/ml in DMF) with a 
water solution of succinylated PGC (20 mg/ml in 
water) at 37 °C resulted in an adduct of PGC-cDDP 
containing 4.3% of platinum by weight [80].  
 In vitro studies showed a 50% inhibition of hu-
man BT-20 adenocarcinoma cell proliferation at a 
PGC-cDDP dose of 0.9 ± 0.2 μM as compared to 0.3 ± 
0.1 μM for free cDDP. Because only free platinum 
complexes are effective in inhibitiing cell division, this 
result suggest that cDDP could dissociate from the 
PGC complex in vitro. Indium-111 labeled PGC-cDDP 
was used to study the kinetics and biodistribution of 
the compound in vivo. We determined that due to a 
long blood half-life of 14 h, PGC-cDDP accumulated 
in rat mammary tumors (13762NF and R3230) at a 
dose that was 5-fold higher (2.5 to 3.5% of the injected 
dose/ gram of tissue) than a control adduct of cDDP 
with a short half life. In vivo imaging using radio-
labeled PGC-cDDP showed high regional activity in 
tumors, whereas the control adduct accumulated 
mainly in the kidneys. This pattern of distribution 
suggested that accumulation in tissue results from 
extravasation of cDDP and release of the drug in the 
tumor. We also found that 80% of the PGC-cDDP 
adduct was eliminated from the circulation 48 h after 
I.V. administration, and exhibited a nearly 5-times 
lower concentration in kidney.  
 In a following study [17] we assessed the thera-
peutic efficacy of PGC-cDDP in a cDDP-sensitive F9 
murine teratoma model. We injected identical doses 
(7.5 mg) of free or PGC-linked cDDP/kg every 3 d. 
Non-treated mice showed a 17-fold increase in tumor 
volume over 30 d after implantation. While animals 
treated with free cDDP showed reduction in tumor 
volume, they also showed an average 24% weight loss 
over the course of 6 d (2 treatments) with 100% mor-
tality. All animals treated with PGC-cDDP survived 
six consecutive treatments over 15 d and showed on 
average a 10% reduction in tumor volume, with 25% 
of the animals showing a complete regression of the 
tumors. The collective results from these studies 
demonstrate that that PGC-succinate can serve as a 
high-capacity carrier for sustained release of cDDP in 
vivo. The drug conjugate shows less systemic toxicity 
than the free drug while retaining antiproliferative 
effectiveness.  
5.3. Non-covalent complexes of drugs and 
PGC 
The obvious advantages of the non-covalent as-
sociation of drugs with drug delivery carriers is in 
scalability, in the ease of formulating 
drugs-containing compositions and in the lack of the 
need to chemically modify the drug molecules. The 
latter is a critical advantage in developing drug de-
livery formulations containing physiologically active 
peptides and proteins, many of which are capable of 
inactivation during chemical modification. The de-
velopment of new formulations and devices for ad-
ministration of such peptides, proteins, as well as low 
molecular weight drugs is driven by the need to 
achieve targeted and highly specific physiological 
effects. With respect to peptides and proteins, many of 
them are unstable in the gastro-intestinal tract and 
therefore may need to be stabilized and protected or 
otherwise delivered via systemic circulation. In addi-
tion, peptides and proteins that have low molecular 
masses tend to have short biological half-lives due to 
their efficient removal from systemic circulation via 
kidneys. A fraction of these peptides and proteins can 
also be removed via reticuloendothelial uptake due to 
recognition by monocyte/macrophages and sinusoi-
dal endothelial cells exacerbated by opsonization of 
drug carriers by the complement system. As a rule, 
many peptides and proteins lose their activity in vivo 
due to proteolysis (peptide bond cleavage). Several 
drug delivery strategies can be useful to circumvent 
these undesirable effects and thus increase peptide 
and protein delivery in vivo. First, a pump can be em-
ployed for continuous systemic drug infusion. This 
strategy is proven efficient in clinical practice but may 
be impractical or disadvantageous for outpatients 
because it restricts mobility, lowers quality of life and 
potentially results in I.V. line infections. Second, pep-
tides and proteins can be included in an implantable 
pump with a membrane allowing diffusion of the 
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drug at a desirable release rate. Due to limited volume 
of these capsules, peptides and proteins are often used 
in a concentrated formulation, which leads to aggre-
gation resulting in loss of solubility and potential loss 
of specific activity. In most cases, the drug is released 
into the extracellular space and is carried by lym-
phatics. Overall concentration of peptide or protein 
may be affected by local lymph node activity and the 
efficacy of lymph node drainage at the implantation 
site. There is also a likelihood of host reaction to cap-
sule material. Third, the drug release system can be 
made biodegradable as a result of encapsulation or 
inclusion into degradable drug delivery vehicles or 
carriers, e.g. polymeric matrices, particles or mem-
brane vesicles (liposomes). These delivery systems are 
usually either implantable or injectable. Implantable 
drug delivery systems are often placed under the ep-
idermis where the components of the system are usu-
ally slowly degraded as a result of biological activity 
of surrounding cells (i.e. as a result of the release of 
enzymes degrading chemical bonds that hold these 
implants together).  
The potential problems associated with the use 
of delivery compositions containing non-covalently 
bound drugs is in their potentially low thermody-
namic stability in solutions that necessitates formu-
lating drug delivery compositions shortly before use. 
This disadvantage is not shared by PGC-based carri-
ers that can be subjected to lyophilization together 
with the drug load due to their cryoprotective prop-
erties [84].  
5.3.1. PGC with hydrophobic cores (HC-PGC) as drug 
carriers  
Most peptides are purified after synthesis using 
reversed phase HPLC because of their affinity for al-
kyl groups covalently linked to the resin. Compared 
to resin with diameter of several microns, PGC has 
diameter of 10 to 50 nm. Despite these small diame-
ters, PGCs can be modified to contain a high density 
of long-chain fatty acid groups covalently linked to 
the PL backbone. Specifically, PGC can be synthesized 
to have a hydrophobic core consisting of stearic acid 
residues covalently linked to PGC (Fig. 12A). Such 
structure has certain similarity to an HPLC carrier 
matrix that is covalently linked to octadecane groups. 
However, unlike a silanol-grafted HPLC matrix, the 
bonds in PGC are peptide and there are also MPEG 
protective chains covalently linked to PL. We have 
previously shown that such “hydrophobic core” 
(HC)-modified PGC is capable of reversibly binding 
peptides/proteins that are then capable of partition-
ing into hydrophobic cores. Alternatively, they can 
have affinity for fatty acids and thus linked to the 
MPEG-grafted PL backbone. One such example, i.e. a 
computer-generated model of leptin non-covalently 
associated with aliphatic chains of HC-PGC, is shown 
in Fig. 12B. The peptide formulation with HC-PGC is 
accomplished by simple co-lyophilization of peptide 
with PGC followed by reconstitution in the injection 
buffer. Peptide formulations prepared in this manner 
demonstrate an extended blood circulation time after 
subcutaneous injection.  
In general, when mixed with an appropriate 
peptide that binds to HC, the resulting HC-PGC for-
mulation is expected to have an affinity-based peptide 
release mechanism. Under normal physiological con-
ditions in vivo, one would expect such pep-
tide-HC-PGC complexes to dissociate due to a deple-
tion of free peptide pool (which depends on kinetic 
and thermodynamic stability of the peptide complex) 
which can accelerate in the presence of fatty-acid 
binding proteins (e.g. serum albumin). However, due 
to steric hindrance imposed by the drug carrier-linked 
MPEG chains [85], which slows down the process of 
peptide displacement from the complex, such compe-
tition is likely a less significant factor in pep-
tide-HC-PGC complex dissociation than in the case 
where MPEG chains were absent. Hydrophilic MPEG 
chains are also the major reason why HC-PGC can 
exist as a colloidal solution in water. The overall hy-
drodynamic diameter of HC-PGC is 20 nm, which 
circumvents the rapid kidney elimination but at the 
same time, enables trafficking from subcutaneous 
sites to the blood, predominantly via the lymphatic 
system.  
Stabilization by PGC is particularly useful for 
peptides that rapidly degrade due to proteolysis. 
Most proteolytic enzymes in the blood have a Mich-
aelis constant (Km) in the range of several micromolar 
and most peptide receptor effective thermodynamic 
constants (Kd) are in the nanomolar range. Therefore, 
for PGC delivery of peptides to be successful, the 
complex of peptide-HC-PGC must have a Kd below 
the enzyme Km but above the receptor Kd (preferably 
<1uM). In the past we tested several highly potent 
small peptides, e.g. glucagon-like peptides (GLP-1 
[19, 86-88], GLP-2), atrial natriuretic peptide (ANP) 
and leptin as potential cargo for loading HC-PGC. 
Below are some of the examples of our efforts directed 
at improving the stability and bioavailability of the 
above peptides in vivo. 
5.3.2. Formulation and HC-PGC-mediated delivery of atrial 
natriuretic peptide (ANP) and leptin. 
 Atrial natriuretic peptide (ANP) and brain na-
triuretic peptide (BNP) are hormones produced by the 
heart that bind to natriuretic peptide receptor A 
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(NPR-A) in target organs (blood vessels, kidney, ad-
renal, and heart) and generate intracellular cGMP 
[89]. They act through many parallel mechanisms to 
promote cardiac output and function, i.e., they an-
tagonize the renin-angiotensin-aldosterone system 
[90-92], inhibit endothelin secretion, reduce systemic 
and renal sympathetic activity, increase natriuretic, 
diuretic and vasorelaxant activity, and act directly on 
the kidney by dilating the afferent arteriole and con-
stricting the efferent arteriole [93, 94]. Thus natriuretic 
peptides (NP) can be viewed as inherent biological 
molecules which are capable of producing most of the 
therapeutic results that are produced by first line 
medications in use today for the treatment of heart 
failure (HF). In addition, NPs may offer additional 
therapeutic benefits in treating patients with HF be-
cause they have the unique ability to inhibit TGF 
induced Smad translocation into the nucleus [95] and 
thus suppress myocardial fibrosis and hypertrophy or 
remodeling [96, 97] which would otherwise lead to 
further heart deterioration in patients with heart dis-
ease. Currently used treatments for HF directly inhibit 
cardiac scarring and remodeling and thus patients 
remain at a greater risk of future cardiac events and 
generally poor long-term outcome. Several studies 
have shown benefits of ANP and BNP in preventing 
cardiac remodeling in ischemic injury. Patients who 
received an infusion of ANP or BNP during or for 2-3 
days after reperfusion procedures have shown de-
creased infarct size, fewer reperfusion injuries, and 
better outcomes (lower incidence of readmission to 
hospital) than controls [98]. 
 Advances in formulation chemistry over the last 
several years have lead to increased clinical use of 
NPs. ANP has a blood half-life of only 2.4 min and, as 
a result, has to be administered as an I.V. infusion. 
BNP also has a short half-life (12.1 min), and has been 
approved for the treatment of HF (also as an infusion). 
Unfortunately, bolus administration of large amounts 
of these peptides leads to hypotension and this effect 
persist (10% incidence) even if lower amounts are 
injected (0.025 µg/kg/min of carperitide) [95]. 
Therefore, the development of a formulation of these 
peptides that has a longer blood half-life would po-
tentially allow patients to self-administer the drug 
outside the hospital setting. Our goal has been the 
development of a long-acting formulation of NP that 
can be used by patients who have received reperfu-
sion treatment to minimize future cardiac events and 
also to improve the long term outcome for those who 
have had mild myocardial infarction without receiv-
ing reperfusion treatment. We envision that the use of 
a PGC drug delivery system will allow the develop-
ment of injectable NPs (ANP and BNP) for use in pa-
tients with both mild and severe myocardial infarc-
tion, thus expanding the benefits of NP therapy to the 
majority of patients suffering from coronary heart 
disease.  
Leptin is a 16 kDa protein hormone that plays a 
key role in regulating energy intake and energy ex-
penditure, including appetite and metabolism. Leptin 
is one of the most important adipose-derived hor-
mones. Leptin binds to the ventromedial nucleus of 
the hypothalamus, known as the "appetite center." A 
small group of humans possess homozygous muta-
tions for the leptin gene, which leads to a constant 
desire for food, resulting in severe obesity [99]. This 
condition can be successfully treated by the admin-
istration of recombinant human leptin [100, 101].  
 Our initial formulation of the HC-PGC complex 
with ANP and leptin was obtained by simply com-
bining HC-PGC and the corresponding peptide in 
isotonic buffered saline. This particular HC-PGC had 
a 20kD PL backbone and a high (55% of the N--amino 
groups) modified with 5kD MPEG, while the re-
maining amino groups were modified by acylation 
with stearic acid N-hydroxysuccinimide ester.  
After 1 h, the mixture was separated using a 
membrane of 100 kD cutoff that efficiently retained 
the HC-PGC complex. The free and the HC-PGC 
bound ANP and leptin complexes were released from 
HC-PGC by treating them with 50% acetonitrile. The 
free and bound ANP and leptin were then analyzed 
by quantitative HPLC which enables estimation of the 
effective Kd value (Fig. 13A). We obtained a Kd value 
of 1.1 uM and determined that each 350kD HC-PGC 
carrier had on average 9 ANP molecules (mol. mass 
3kD) bound to it. Leptin formed a more stable com-
plex with HC-PGC (Fig. 13A). It should be noted, that 
estimation of effective Kd values reflecting the affinity 
of leptin and ANP to HC-PGC shows that the affinity 
correlates with GRAVY index (hydropathicity of lep-
tin is greater than ANP), while the capacity of 
HC-PGC carrier inversely correlates with peptide 
mass (ANP<leptin).  
The pharmacokinetic profile of the PGC-ANP 
formulation was determined in mice at various time 
points using ELISA of blood serum after intravenous 
administration of either free ANP or HC-PGC-ANP. 
Data were corrected for endogenous background 
ANP. It should be noted that mice have a higher 
metabolic rate than humans and the conversion factor 
(mouse to human) in dosing is 12:1 to 9:1 [102]. Hy-
drophobic core-PGC bound ANP had an extended 
circulation time compared to non-conjugated peptide 
and the extension of circulation was a function of the 
ratio of peptide to PGC (Fig. 13B). It is clear that re-
versible association of peptides with HC-PGC enables 
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sustained release after systemic administration in 
mice (2µg peptide/animal, n=4, group) with a re-
sultant large increase of area under the curve (AUC). 
 
 
 
Figure 12. HC-PGC as a drug carrier. A- a computer generated model of HC-PGC fragment with MPEG protective chains (shown 
space filled) and hydrophobic elements represented by fatty acid residues; B – a computer simulated representation of a leptin molecule 
binding to the hydrophobic “core”. Interacting surfaces are shown in green and grey for leptin and HC-PGC, respectively. The modeling 
is performed in MOE (Laboratory of Molecular Imaging Probes, Univesity of Massachusetts Medical School). 
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Figure 13. Polypeptide binding to HC-PGC and the release of HC-PGC bound cargo after the I.V. administration. A - 
The binding of atrial natriuretic peptide (ANP) and leptin to HC-PGC. The affinity to HC-PGC correlates with GRAVY index (hydro-
pathicity, leptin>ANP) and the capacity of HC-PGC carrier inversely correlates with peptide mass (ANP<leptin). B – reversible associ-
ation of ANP with HC-PGC enables sustained release after intravenous administration in mice (2µg peptide/animal, n=4, group) with a 
resultant strong increase of AUC compared to native ANP (Data provided by Pharmain Corp. Seattle WA). 
 
6. Conclusions and perspectives. 
As summarized in this review, the development 
of MPEG-protected polyamino acids has resulted in 
one of the most successful graft-copolymers to date 
for use as a carrier of potential diagnostic and thera-
peutic agents. Much of the potential of PGC lies in its 
versatility and ease of chemical modification and thus 
adaptation for delivering both convalently and 
non-covalently linked cargo. PGC can be engineered 
as a covalent amphiphile that is capabe of binding to 
hydrophobic residues of small proteins and peptides 
resulting in a “hydrophobic core” (HC)-modified 
PGC formulation that acts as an affinity-based peptide 
release mechanism. PGCs can also be made with zinc 
bridges for anchoring zinc-binding proteins. 
Alternately, non-covalent attachment can be designed 
for carriers containing physiologically active peptides 
and proteins, many of which are rendered inactive 
upon chemical modification. PGC-based carries can 
be synthesized relatively inexpensively and on a large 
scale bases for commercial applications. Most im-
portantly, these formulations are expected to remain 
stable in solutions or in lyophilized form for extended 
periods of time.  
 PGCs offer a plurality of advantages in 
comparison to other carries designed using PEGyla-
tion technology, e.g., multiple available linking sites 
for drug and adaptor molecules, long circulation 
times without compromised biodegradability, and no 
toxicity or immunogenicity. The safety and 
biocampatability profile of PGC has in fact resulted in 
its being one of the few 100% synthetic 
non-proteinaceous macromolecules that has suceeded 
in passing the initial safety phase of clinical trials. This 
safety profile, along with the capability of MPEGs to 
protect the inner drug cargo from uptake and degra-
dation, forms the bases of its outstanding potential for 
use in the development of a wide range of future 
therapeutic and diagnostic agents.  
 PGCs conjugated to contrast agents such as 
paramagnetic gadolinium are capable of long 
circulation times after injection into the blood stream 
and as such offer advantages in angiographhic 
imaging applications used for the assesment of 
disease related vascular pathologies. These should be 
of greatest utility in cases such as stroke and GI 
bleeding when timely diagnosis is key to positive pa-
tient outcome and will also be beneficial in chronic 
diseases such as cancer where assessment of tumor 
vascularity following therapeutic intervention is crit-
ical for further treatment planning. In addition, be-
cause of their extravasation that is highly atypical in 
normal tissues, PGC-based therapeutic agents can 
accumulate in diseased tissue in sufficient quantities 
to be of therapeutic benefit. On the same bases, ac-
cumulation of enzyme sensing PGC-based imaging 
agents allows for amplification of diagnostic signal 
and thus higher sensitivity detection of pathological 
changes occurring at the cellular and tissue level. 
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Furthermore, PGC technology applied to 
near-infrared fluorophores as optical imaging probes 
is also anticipated to have a number of advantages in 
detection of tumors accessible to clinical optical im-
aging applications (i.e., those within 7-10 mm of the 
skin surface such as breast, prostate, and colon can-
cers), especially given the demonstrated sensitivity of 
these probes (detecting subnanomole levels of tu-
mor-associated enzymes). These probes may prove 
invaluable in the differential diagnosis and staging of 
cancers. A future, but as yet untested use of 
PGC-based carriers is in non-viral delivery of genes 
and other nucleotides such as for the delivery of 
siRNA. As a non-modified copolymer, PGC carries 
multiple positive charges and can potentially form 
polyionic complexes with polyanions, e.g. plasmid 
DNA. 
 In conclusion, the chemical versatility, safety, 
cost-effectiveness and tissue permeability and acces-
sibility profile of PGC-based compounds offers an 
exciting pathway for future development of highly 
sensitive and targeted diagnostics and therapeutics.  
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